Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Grifols Therapeutics LLC)"
Count: 64
Selected: 0
| NCT ID | Title |
|---|
| NCT03095287 | Alphanate in Immune Tolerance Induction Therapy | ||
| NCT02872142 | Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis | ||
| NCT02870348 | Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE) | ||
| NCT02870309 | Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency | ||
| NCT03702920 | Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5% | ||
| NCT03451292 | Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites | ||
| NCT02472665 | Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease | ||
| NCT02281500 | Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia | ||
| NCT05645107 | A Study to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment (SMT) Compared to Placebo Plus SMT to Prevent Infections in Participants With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia | ||
| NCT04847141 | A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients | ||
| NCT04722887 | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency | ||
| NCT04566692 | A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency | ||
| NCT04561115 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency | ||
| NCT04547140 | Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19) | ||
| NCT04480424 | Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19) | ||
| NCT03814798 | Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary Immunodeficiency | ||
| NCT03351933 | Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human) | ||
| NCT02806986 | Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency | ||
| NCT02796937 | Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency | ||
| NCT02604810 | Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency | ||
| NCT02473965 | Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis | ||
| NCT02473952 | A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis | ||
| NCT02413580 | A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations | ||
| NCT02282527 | A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency | ||
| NCT02139657 | An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human) | ||
| NCT02093221 | Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus | ||
| NCT02037555 | Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass | ||
| NCT01983241 | Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) | ||
| NCT01684410 | Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis | ||
| NCT01465958 | Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency | ||
| NCT01222117 | A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion | ||
| NCT01213043 | Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency | ||
| NCT01014975 | A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients | ||
| NCT00486837 | Deposition of Inhaled Prolastin in Cystic Fibrosis Patients | ||
| NCT00437671 | Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels | ||
| NCT00418483 | A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion | ||
| NCT00389324 | A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency | ||
| NCT00301366 | The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency | ||
| NCT00295061 | Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults | ||
| NCT00263887 | Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE) | ||
| NCT00220805 | Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration | ||
| NCT00220779 | Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis | ||
| NCT00220766 | Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients | ||
| NCT00220740 | Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | ||
| NCT00220727 | Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP | ||
| NCT04055389 | Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis | ||
| NCT02104245 | Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4) | ||
| NCT01841619 | IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus | ||
| NCT01515007 | Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3) | ||
| NCT01179893 | Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis |
